AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03592771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE App
Description: Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
Study NCT03592771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Feedback Messages
Description: Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
Study NCT00907322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 20 mg Dimebon, single dose
Study NCT00907322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 40 mg Dimebon, single dose
Study NCT00907322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; 60 mg Dimebon, single dose
Study NCT00907322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Oral tablet; placebo, single dose
Study NCT04778891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Medication Management services
Description: Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
Study NCT05315934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper body aerobic exercise
Description: Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
Study NCT05315934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body aerobic exercise
Description: Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT02704416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: catheter ablation of fragmented signal in the right ventricular outflow tract
Study NCT02704416 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter Ablation
Description: catheter ablation of fragmented signal in the right ventricular outflow tract
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medaxis Debritom+
Description: Advanced micro fluid jet therapy to clean and stimulate wound
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sharp Surgical Debridement
Description: Scalpel or Curette to clean and debride wound
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Application
Description: Application of moisture retentive dressing, and a multi layer compression dressing
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Application
Description: Application of moisture retentive dressing, and a multi layer compression dressing
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibracol Wound Dressing
Description: Application of a collagen alginate dressing
Study NCT04564443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of a collagen alginate dressing
Study NCT04464759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
Study NCT04464759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
Study NCT04464759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Combination of nivolumab, hydroxychloroquine and ipilimumab
Study NCT01433614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 i.v. every 3 weeks, both study arms
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT01433614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
Study NCT01433614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
Study NCT04495348 — intervention group
Intervention type: DRUG
Intervention: Doravirine
Description: Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
Study NCT01201382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-AST
Description: A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
Study NCT01201382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Counseling
Description: Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
Study NCT02028065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
Study NCT02028065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a single IV bolus over 10 seconds
Study NCT00954070 — intervention group
Intervention type: DEVICE
Intervention: Confocal endomicroscope (Pentax Model EC3870K)
Description: The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
Study NCT03358121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clamp study
Description: Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
Study NCT04397224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: Ventriculo-ventricular conduction time measurement using device analyzer
Study NCT03667924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PorchLight Project
Description: Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
Study NCT02707965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin sodium (brand name vs generic drugs)
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study NCT00422448 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: To test the frequency of BRAF and NRAS mutations among nevi
Description: Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
Study NCT03949504 — intervention group
Intervention type: PROCEDURE
Intervention: New Find-risk questionnaire software
Description: FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
Study NCT00576628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Description: Recommended starting dose 1.2 micrograms/kg sc monthly
Study NCT01173107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: colchicine 1T tid
Study NCT03685474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears - School Based
Description: Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
Study NCT03685474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
Study NCT02516982 — intervention group
Intervention type: OTHER
Intervention: Whooley Questions
Description: The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
Study NCT02516982 — intervention group
Intervention type: OTHER
Intervention: Edinburgh Postnatal Depression Scale
Description: The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
Study NCT02516982 — intervention group
Intervention type: OTHER
Intervention: Momentary questions
Description: These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
Study NCT02516982 — intervention group
Intervention type: OTHER
Intervention: Contextual questions
Description: Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
Study NCT04136548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study NCT04136548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study NCT05050968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
Study NCT00922376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone telehealth application: Think Positive (T+)
Description: T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
Study NCT01503684 — intervention group
Intervention type: OTHER
Intervention: Determined by intended physician
Description: We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
Study NCT01360814 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01360814 — intervention group
Intervention type: BEHAVIORAL
Intervention: telephone-based intervention
Description: Receive multidisciplinary structured intervention
Study NCT01360814 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01360814 — intervention group
Intervention type: OTHER
Intervention: counseling intervention
Description: Receive multidisciplinary structured intervention
Study NCT01360814 — intervention group
Intervention type: BEHAVIORAL
Intervention: exercise intervention
Description: Receive multidisciplinary structured intervention
Study NCT01360814 — intervention group
Intervention type: OTHER
Intervention: educational intervention
Description: Receive multidisciplinary structured intervention
Study NCT01360814 — intervention group
Intervention type: BEHAVIORAL
Intervention: telephone-based intervention
Description: Receive standard care
Study NCT01360814 — intervention group
Intervention type: PROCEDURE
Intervention: standard follow-up care
Description: Receive standard care
Study NCT04314700 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT- based investigational imaging device
Description: Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
Study NCT03332173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Oral administration using 80 mg capsules
Study NCT04073862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stepped-Care TF-CBT
Description: SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
Study NCT03060915 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polysomnography
Description: Patient's undergo a polysomnography
Study NCT03510104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules
Study NCT00909051 — intervention group
Intervention type: DRUG
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Patients with diabetes type 2 newly treated with Glucobay
Study NCT02812160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatz3 Adjustable Balloon
Description: An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
Study NCT01654029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centred Communication Intervention
Description: The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
Study NCT02421523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aim 2 Exercise group
Description: The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.